RPG Life Sciences Limited (RPGLIFE.NS)
- Previous Close
2,170.90 - Open
2,160.00 - Bid 2,142.60 x --
- Ask 2,144.70 x --
- Day's Range
2,143.40 - 2,192.40 - 52 Week Range
1,381.00 - 2,974.95 - Volume
3,476 - Avg. Volume
21,912 - Market Cap (intraday)
35.476B - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
19.37 - EPS (TTM)
110.72 - Earnings Date Jul 18, 2025 - Jul 19, 2025
- Forward Dividend & Yield 16.00 (0.74%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
--
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
www.rpglifesciences.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RPGLIFE.NS
View MorePerformance Overview: RPGLIFE.NS
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPGLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPGLIFE.NS
View MoreValuation Measures
Market Cap
35.90B
Enterprise Value
34.65B
Trailing P/E
19.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.49
Price/Book (mrq)
--
Enterprise Value/Revenue
5.30
Enterprise Value/EBITDA
13.59
Financial Highlights
Profitability and Income Statement
Profit Margin
28.04%
Return on Assets (ttm)
14.76%
Return on Equity (ttm)
40.48%
Revenue (ttm)
6.53B
Net Income Avi to Common (ttm)
1.83B
Diluted EPS (ttm)
110.72
Balance Sheet and Cash Flow
Total Cash (mrq)
2.66B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
327.5M